Skip to main content
Premium Trial:

Request an Annual Quote

Ampersand Ventures, Signature Genomic Laboratories, Erasmus Medical Center, Illumina, Partek, Quimica Valaner, Finnish Red Cross, GeneGo

Premium
Ampersand Ventures Invests in Signature Genomic Laboratories
 
Ampersand Ventures, a private equity firm focusing on investments in the healthcare and industrial technology sectors, said last week that it has acquired a stake in Signature Genomic Laboratories. The percentage of the stake and the size of the investment were not discussed.
 
In conjunction with the investment, Ampersand partners David Parker and Herbert Hooper have been appointed to Signature’s board of directors. Sacred Heart Medical Center and Pathology Associates Medical Laboratories are also investors in the Spokane, Wash.-based company.
 

 
Erasmus to Use Illumina's 610-Quad BeadChips in Fetal Abnormality Study
 
The Erasmus Medical Center will use Illumina’s BeadChips in a 10,000-subject study aimed at identifying early environmental and genetic causes of abnormal growth in fetal development, Illumina said last week.
 
The Rotterdam, Netherlands-based research hospital has bought Illumina’s Infinium HD Human610-Quad BeadChips for the Generation R Study, which is backed in part by the Dutch government, industry partners, and the hospital.
 
Erasmus used Illumina’s HumanHap 550 BeadChip in a similar study of 10,000 individuals that was focused on late-age disease development, according to Andre Uitterlinden, from the hospital’s Internal Medicine department. The latest BeadChip will allow researchers to boost their throughput four times compared to the 550, he added.
 
Illumina said the 610-Quad, in addition to its extra 60,000 genetic markers, also includes proprietary CNV content the company developed through a collaboration with Decode Genetics.
 
Financial terms of the agreement were not released.
 

 
Partek Signs up Mexico Distributor for Software
 
Quimica Valaner will distribute Partek’s biosciences statistical and interactive data visualization software in Mexico, Partek said.
 
Under the agreement, Quimica Valamer will provide sales and marketing for the entire Partek software line, including Genomics Suite, Discovery Suite, QSAR Solution, and the Screener’s Solution, to the scientific communities in Mexico.
 
Financial terms of the agreement were not released.
 

 
Finnish Red Cross to Use GeneGo's Software for Blood, Transplant Studies
 
The Finnish Red Cross has licensed GeneGo’s bioinformatics software for use in clinical and research projects it plans to conduct on blood taken from transfusion patients, GeneGo said last week.
 
The FRC Blood Service will use the MetaCore and MetaDrug bioinformatics and chemoinformatics suites for blood group and cell type analysis from blood transfusions as well as for tissue typing of donors involved in organ, bone marrow, cord blood, and bone marrow stem cell replacement transplants.
 
MetaCore 5.0 is used to help target, validate, and identify biomarkers for disease states and toxicology, and MetaDrug 5.0 is used to predict toxicity, metabolism, and the effects of novel small molecules.
 

Financial terms of the agreement were not released.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.